The primary pathways through which Icaritin exerts its anti-HCC effects include cancer pathways, PI3K-Akt signaling pathway, MAPK signaling pathway, resistance mechanisms to inhibitors of the epidermal growth factor receptor tyrosine kinase, and the HCC pathway. This evidence concerns the gene AKT1 and cancer.